Health1 min read

As cancer treatments become more effective, we must ask: what is life like for the people who receive them? | Ranjana Srivastava

By · Via The Guardian Science · Published by Everything Blog

In short

Combining an experimental mRNA vaccine with pembrolizumab significantly reduced recurrence risks for melanoma patients, but quality-of-life assessments from the trial remain unreleased. Daily side effects such as fatigue, neuropathy, and cognitive fog frequently prevent patients from working, resting, or tending to household obligations. Despite these substantial daily challenges, less than a third of clinical trials currently include quality-of-life data in their primary published findings.

Key points

  • Advancing cancer treatments can delay disease recurrence while simultaneously exposing pa…: Advancing cancer treatments can delay disease recurrence while simultaneously exposing patients to burdensome daily side effects.
  • Clinical research persistently underreports patient well-being, leaving doctors with inco…: Clinical research persistently underreports patient well-being, leaving doctors with incomplete data regarding daily functional outcomes.
  • Experts recommend that future adjuvant trials report the frequency, duration, and recover…: Experts recommend that future adjuvant trials report the frequency, duration, and recovery timelines of meaningful physical deteriorations.

Sources checked by our analysis pipeline: 1

Two decades ago, a dear friend called me in a trembling voice. Was there hope for his young nephew, whose cancer had spread to the brain? Sadly, “no”, I said. But today, for such patients, there are options that were unimaginable back then.

Recently, researchers at the European Society For Medical Oncology presented the latest chapter results from a randomised controlled trial of a bespoke cancer vaccine for patients with high-risk melanoma. The trial involved 1,137 patients whose melanoma had been surgically removed but remained at high recurrence risk. They received either pembrolizumab, an established immunotherapy, or pembrolizumab combined with an experimental mRNA vaccine, designed to help the immune system recognise and attack targets unique to the patient’s tumour.

At two years, 82.2% of those who received the combination were alive without their cancer returning, compared with 70% of those given pembrolizumab alone – a difference of about 12 percentage points. The combination also reduced the relative risk of distant metastasis or death by 38%.

These results raise the prospect that personalised vaccines could become an important addition to cancer…

Health